Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways.

COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.

In this episode:

• Personal journey and battles with anxiety, and seeking psychiatric help
• The subjective experience of psilocybin and impact of emotional processing and cognitive function
• Birth of COMPASS
• The current landscape of the research
• Models for therapies and how they can scale
• Research questions that need to be addressed
• COMPASS decision to patent psilocybin (and what this means for its scientific exploration)
• Rescheduling psilocybin

Links:

COMPASS Pathways

Support the podcast:

Support the podcast (Patreon)

Support the mission:

Mind Medicine Australia

Donate to Mind Medicine Australia

Join a local chapter

Support this show http://supporter.acast.com/mind-medicine-australia.

Hosted on Acast. See acast.com/privacy for more information.